SR 33805 oxalate
Potent Ca2+ channel antagonist; binds allosterically to the a1-subunit of L-type Ca2+ channels (Kd = 20 pM), at a site distinct from other types of blocker. Shows some selectivity for vascular smooth muscle, inducing vasorelaxation without producing inotropic or chronotropic effects. Inhibits PDGF-stimulated smooth muscle cell proliferation.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 654.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.53 mL||7.64 mL||15.27 mL|
|5 mM||0.31 mL||1.53 mL||3.05 mL|
|10 mM||0.15 mL||0.76 mL||1.53 mL|
|50 mM||0.03 mL||0.15 mL||0.31 mL|
References are publications that support the biological activity of the product.
Chatelain et al (1993) In vitro characterization of a novel Ca2+ entry blocker: SR 33805. Eur.J.Pharmacol. 246 181 PMID: 8223943
Magnier-Gaubil et al (1996) Smooth muscle cell cycle and proliferation. Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ATPase regulation. J.Biol.Chem. 271 27788 PMID: 8910375
Romey and Lazdunski (1994) Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J.Pharmacol.Exp.Ther. 271 1348 PMID: 7996445
If you know of a relevant reference for SR 33805 oxalate, please let us know.
View Related Products by Product Action
Keywords: SR 33805 oxalate, SR 33805 oxalate supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, voltage-gated, voltage-dependent, SR33805, oxalate, Voltage-gated, 1806, Tocris Bioscience
1 Citation for SR 33805 oxalate
Citations are publications that use Tocris products. Selected citations for SR 33805 oxalate include:
Wu et al (2008) Coupling of L-type Ca2+ channels to KV7/KCNQ channels creates a novel, activity-dependent, homeostatic intrinsic plasticity. J Neurophysiol 100 1897 PMID: 18715900
Do you know of a great paper that uses SR 33805 oxalate from Tocris? Please let us know.
Reviews for SR 33805 oxalate
There are currently no reviews for this product. Be the first to review SR 33805 oxalate and earn rewards!
Have you used SR 33805 oxalate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.